Soleno Therapeutics (SLNO) Net Equity Issued and Repurchased (2015 - 2023)

Soleno Therapeutics' (SLNO) quarterly Net Equity Issued and Repurchased came in at -$7.1 million in Q3 2023, down 3636.32% on a QoQ basis from -$190000.0 in Q3 2020.

Soleno Therapeutics (SLNO) Net Equity Issued and Repurchased (2015 - 2023) Analysis & Trends

Soleno Therapeutics (SLNO) has 5 years of Net Equity Issued and Repurchased data on file, last reported at -$7.1 million in Q3 2023.

  • On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to -$7.1 million in Q3 2023; TTM through Dec 2024 was -$7.1 million, a 2.61% increase from a year earlier, with the FY2025 full-year figure at $215.7 million, up 44.82% from the prior year.
  • Net Equity Issued and Repurchased for Q3 2023 stood at -$7.1 million, down from -$190000.0 in the prior quarter.
  • Over the last five years, Net Equity Issued and Repurchased for SLNO reached as high as -$190000.0 in Q3 2020 and fell as low as -$7.1 million in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 141.90 Mn
10 Soleno Therapeutics 874.25 Mn 618.67 Mn 93.41 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2023 -7.10 Mn
Sep 30, 2023 -7.10 Mn
Sep 30, 2020 -190,000.00
Sep 30, 2020 -190,000.00
Mar 31, 2017 10.00 Mn
Mar 31, 2017 10.00 Mn
Dec 31, 2016 -70,000.00
Dec 31, 2016 -70,000.00
Jun 30, 2016 70,000.00
Jun 30, 2016 70,000.00
Dec 31, 2015 194.00
Dec 31, 2015 194.00
Sep 30, 2015 1.43 Mn
Sep 30, 2015 1.43 Mn